STAR-LLD-OCR

STAR-LLD-OCR is an oral controlled-release formulation of lenalidomide being developed by Starton Therapeutics. It utilizes a continuous low-dose delivery platform (STAR-LLD) designed to maintain therapeutic levels of lenalidomide while potentially reducing the hematologic toxicities associated with standard pulsatile oral dosing (e.g., Revlimid). Lenalidomide is an immunomodulatory drug (IMiD) that acts by binding to cereblon (CRBN), a component of the CRL4-CRBN E3 ubiquitin ligase complex. This binding triggers the selective ubiquitination and subsequent proteasomal degradation of lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos), leading to anti-neoplastic and immunomodulatory effects. The OCR formulation is specifically being investigated for high-risk relapsed/refractory multiple myeloma and chronic lymphocytic leukemia.

Other names

lenalidomide (continuous low-dose formulation)oral controlled-release lenalidomide